Sloan Kettering Seeks More Sanctions In Drug IP Case

By Matthew Guarnaccia (February 9, 2017, 3:33 PM EST) -- The Sloan Kettering Institute again asked a New York federal judge to sanction a biopharmaceutical company and its counsel in a now-dismissed lawsuit over gene therapy patent rights, saying Wednesday the company used protected documents from this case in a newly filed state court matter concerning the same issues.

U.S. District Judge Alison J. Nathan in January had allowed Errant Gene Therapeutics LLC to dismiss its own case and refile the suit against the Manhattan-based cancer research center in New York state court. The dispute is related to the ownership of patents for a blood disorder treatment. But Errant and Niro...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.

  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!


Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!